Proceedings · Session S-585 · filed November 17, 2026

Lab Technology & MethodsSession paper

Currus Biologics Cuts Lentiviral Vector Use in CUR-001 Via Automation

Currus Biologics cut lentiviral vector use in CUR-001 production by moving to the automated Cocoon platform, with Cell Therapies in Melbourne set to supply its planned Phase I trial.

By Sophie Lindqvist3 min read647 words

Summary

  • Currus Biologics reduced lentiviral vector requirements for CUR-001, a solid tumor cell therapy candidate, by moving production to the automated Cocoon platform.
  • The optimized process has been transferred to Melbourne contract manufacturer Cell Therapies (CTPL) to supply a planned Phase I trial.
  • Octane Biotech re-acquired the Cocoon platform from Lonza in March; both firms supported the Currus automation project.
  • CEO Sam Cobb said modular Cocoon units allow capacity expansion without changing the manufacturing process.
  • Cobb expects wider automation of steps like cell selection, activation, modification, expansion and harvest, but not fully autonomous manufacturing.
Automation a Path to Lower Cell Therapy Costs
FigureAutomation a Path to Lower Cell Therapy Costs — whitesession / pixabay

Australian cell therapy developer Currus Biologics says it has significantly reduced the amount of lentiviral vector needed to manufacture CUR-001, its candidate autologous therapy for solid tumors, by transferring production to an automated platform — a change with direct implications for batch cost and process consistency.

CEO Sam Cobb outlined the project this week in an interview with GEN. To minimize manual handling, the company moved the existing CUR-001 manufacturing process onto the Cocoon automated production platform, a system originally developed by Octane Biotech and controlled until recently by Swiss CDMO Lonza. Octane re-acquired the technology in March.

"This involved optimizing several key manufacturing parameters, including the amount of lentiviral vector required for transduction, cell densities during seeding and transduction, and the use of different starting materials," Cobb said.

What changed in the process?

Lentiviral vector is one of the largest cost drivers in CAR T and related cell therapy production, so any reduction in vector use translates directly into lower cost of goods. Cobb framed the result in those terms.

"Importantly, this optimization enabled us to reduce the amount of lentiviral vector required for manufacturing, which has the potential to significantly reduce manufacturing costs," she said.

She was careful to draw a line between process change and product change: "The objective was not to change the fundamental biology of CUR-001, but to establish a more consistent, reproducible, and efficient manufacturing process that can support future clinical and commercial development."

The optimized process has now been transferred to Cell Therapies (CTPL), a contract manufacturer based in Melbourne, which will produce CUR-001 for Currus' planned Phase I clinical trial program. Currus did not disclose the scale of the vector reduction or comparative cost figures, and the claim has not been verified by third-party data — a distinction R&D managers weighing similar platform moves should keep in mind.

Lonza and Octane Biotech both supported the automation project, giving Currus access to platform expertise during technology transfer.

Why modular capacity matters for scale-up

Beyond cost, Cobb pointed to the platform's modular architecture as the reason automation should ease the path from clinical supply to commercial launch.

"One of the advantages of the Cocoon platform is its modular design, which allows manufacturing capacity to be expanded by adding additional units rather than fundamentally changing the manufacturing process," she said.

That expansion model matters for autologous therapies, where each patient requires an individual batch and capacity grows patient by patient rather than through larger bioreactors. Still, Currus has not committed to Cocoon for commercial supply.

"A final decision on commercial manufacturing will depend on clinical outcomes, regulatory requirements, anticipated patient demand, manufacturing capacity, and commercial economics," Cobb said.

How far can cell therapy automation go?

Cobb expects process automation to become more common across CAR T manufacturing, but she does not see fully autonomous plants as the end point.

"One of the major barriers to broader adoption of autologous CAR T cell therapies is the complexity and cost of manufacturing individual patient batches. Automation provides a way to address both challenges while improving process standardization," she said.

In her assessment, several core unit operations are already automatable today:

  • cell selection
  • cell activation
  • genetic modification
  • cell expansion
  • harvest

Other steps remain harder to automate, including material collection, sampling for quality control, batch review and release, cryopreservation, and distribution. Some of these may still become more automated over time, but Cobb argued that full autonomy is not the gate for efficiency gains.

"Some of these activities may also become increasingly automated, but I do not think fully autonomous manufacturing is a prerequisite for achieving meaningful improvements in efficiency," she said.

For Currus, the immediate test is execution: CTPL must now deliver Phase I supply using the optimized process, and the consistency gains Cobb claims will only be measurable once clinical-grade batches run at the contract site.

via finance.yahoo.com (Original)

Filed under

  • cell-therapy-manufacturing
  • car-t
  • lentiviral-vectors
  • process-automation
  • technology-transfer
Share this article:

More from Sophie Lindqvist

Sophie Lindqvist

Show full bio

Correspondent covering money, funding and market shifts around research and development at Hypothesis Wire.

242 articles

References

  1. No Universal Winner in rAAV Manufacturing Economics, Study Finds
  2. 66% to 90%: The Outsourcing Numbers Driving CGT Contracting
  3. WHO's 15-Partner mRNA Programme Tests the Industry's Manufacturing Playbook
  4. iPSC Programs Fail Early on Bad Starting Cell Lines, Pluristyx Warns
  5. S2N.Bio starts Alzheimer's cell therapy tech transfer in Melbourne

« Previous articleNext article »